| 000 | 01522 a2200385 4500 | ||
|---|---|---|---|
| 005 | 20250517003912.0 | ||
| 264 | 0 | _c20150629 | |
| 008 | 201506s 0 0 eng d | ||
| 022 | _a1527-3792 | ||
| 024 | 7 |
_a10.1016/j.juro.2014.11.094 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aOelke, Matthias | |
| 245 | 0 | 0 |
_aTime to onset of clinically meaningful improvement with tadalafil 5 mg once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: analysis of data pooled from 4 pivotal, double-blind, placebo controlled studies. _h[electronic resource] |
| 260 |
_bThe Journal of urology _cMay 2015 |
||
| 300 |
_a1581-9 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Randomized Controlled Trial | ||
| 650 | 0 | 4 |
_aCarbolines _xadministration & dosage |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLower Urinary Tract Symptoms _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPhosphodiesterase 5 Inhibitors _xadministration & dosage |
| 650 | 0 | 4 |
_aProstatic Hyperplasia _xcomplications |
| 650 | 0 | 4 | _aRemission Induction |
| 650 | 0 | 4 | _aTadalafil |
| 650 | 0 | 4 | _aTime Factors |
| 700 | 1 | _aShinghal, Rajesh | |
| 700 | 1 | _aSontag, Angelina | |
| 700 | 1 | _aBaygani, Simin K | |
| 700 | 1 | _aDonatucci, Craig F | |
| 773 | 0 |
_tThe Journal of urology _gvol. 193 _gno. 5 _gp. 1581-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.juro.2014.11.094 _zAvailable from publisher's website |
| 999 |
_c24392612 _d24392612 |
||